To study the efficacy and safety of combination treatment using allopurinol and fenofibrate in patients with Hyperuricemia. | [Pakistan Journal of Pharmacology • 2012]

Author(s):

1. Irfan Zafar: Department of Pharmacology and Therapeutics, Hamdard College of Medicine & Dentistry, Hamdard University, Karachi, Pakistan

2. Moosa Khan: Department of Pharmacology and Therapeutics, BMSI, Jinnah Postgraduate Medical Center, Karachi, Pakistan

3. Abdul Manan Junejo: Department of Nephrology, Jinnah Postgraduate Medical Center, Karachi, Pakistan

4. Syeda Zain: Department of Pharmacology and Therapeutics, Sir Syed College of Medical Sciences for Girls, Karachi, Pakistan

Abstract:

Allopurinol is the most frequently used antihyperuricemic drug. Fenofibrate, a derivative of fibric acid, is commonly used in the treatment of hyperlipidemia. Fenofibrate treatment has been shown to decrease serum urate levels. This study was conducted to compare the efficacy and safety of combination treatment using allopurinol 100mg and fenofibrate 67mg daily with allopurinol 300mg daily. Sixty hyperuricemic patients with serum uric acid level 7.0mg per deciliter or above were enrolled and assigned to take either allopurinol 300mg or combination treatment using allopurinol 100mg + fenofibrate 67mg daily for 12 weeks. Drug efficacy was assessed by measuring percentage of subjects achieving serum uric acid level less than 6mg per deciliter at day 90. Drug efficacy was also assessed by measuring percent change in serum uric acid level from day 0 to day 90. Safety of the drug was assessed by reviewing adverse effects (AEs) and laboratory values. Comparison of percentage of subjects reaching serum uric acid level less than 6.0mg per deciliter at day 90 between the two groups was highly significant (P=0.001). Similarly percent change in serum uric acid level from day 0 to day 90 was also highly significant between the two groups (P=0.001). Our results showed that allopurinol 300mg once daily is more effective than combination treatment using allopurinol 100mg plus fenofibrate 67mg. However proportions of subjects experiencing any adverse event were higher in allopurinol 300mg group. Similarly the adverse effects leading to treatment withdrawal were higher in allopurinol group. Allopurinol 300mg once daily is more effective antihyperuricemic agent than combination treatment using allopurinol 100mg plus fenofibrate 67mg.

Page(s): 55-60

DOI: DOI not available

Published: Journal: Pakistan Journal of Pharmacology, Volume: 29, Issue: 1, Year: 2012

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views